Collegeville, PA, United States of America

Stuart Paul Romeril

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Chemical Compounds. Top assignees: Glaxosmithkline LLC, Glaxosmithkline Intellectual Property Development Limited, Glaxosmithkline Intellectual Property (No.2) Limited. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stuart Paul Romeril. Retrieved from https://idiyas.com/inventor/stuart-paul-romeril

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 35.7

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 9.4

ph-index = 5

Forward Citations = 83(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

2 out of 95

Glaxosmithkline Intellectual Property (No.2) Limited

patents

4. 1 out of 269

Cancer Research Technology Limited

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Substituted Pyridines

DNMT1 Inhibitors

STING Modulators

Enhancer Of Zeste Homolog 2

Indoles

Azaindazoles

Indazoles

Chemical Compounds

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12285436 - Substituted pyridines as DNMT1 inhibitors (2025-04-29),

2. 11771711 - Substituted pyridines as DNMT1 inhibitors (2023-10-03),

3. 11377440 - Modulators of stimulator of interferon genes (STING) (2022-07-05),

4. 10975056 - Substituted pyridines as inhibitors of DNMT1 (2021-04-13),

5. 9790212 - Enhancer of zeste homolog 2 inhibitors (2017-10-17),

6. 9505745 - Enhancer of zeste homolog 2 inhibitors (2016-11-29),

7. 9402836 - Indoles (2016-08-02),

8. 9073924 - Azaindazoles (2015-07-07),

9. 9018382 - Indazoles (2015-04-28),

10. 8975291 - Indoles (2015-03-10),

11. 8846935 - Indazoles (2014-09-30),

12. 8697685 - Chemical compounds (2014-04-15),

13. 8637509 - Azaindazoles (2014-01-28),

14. 8598156 - Chemical compounds (2013-12-03),

Title: The Innovative Contributions of Stuart Paul Romeril

Introduction

Stuart Paul Romeril is a notable inventor based in Collegeville, PA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, Romeril has made strides in developing innovative compounds that target critical health issues.

Latest Patents

Among his latest patents, Romeril has focused on substituted pyridines as DNA methyltransferase 1 (DNMT1) inhibitors. This invention relates to substituted pyridine derivatives that inhibit the activity of DNMT1. The invention also encompasses pharmaceutical compositions that include these compounds and methods for using them in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity.

Career Highlights

Throughout his career, Romeril has worked with prominent companies such as GlaxoSmithKline LLC and GlaxoSmithKline Intellectual Property Development Limited. His work in these organizations has allowed him to contribute to the advancement of medical science and therapeutic solutions.

Collaborations

Romeril has collaborated with esteemed colleagues, including William Henry Miller and Neil W Johnson. These partnerships have further enriched his research and development efforts.

Conclusion

Stuart Paul Romeril's innovative work in the pharmaceutical industry, particularly in developing DNMT1 inhibitors, showcases his commitment to addressing significant health challenges. His contributions continue to impact the field positively.

Profile summary based on public USPTO records.